Presenting Companies

Transcription

Presenting Companies
Wednesday, October 3, 2007
11:15
11:30
11:45
12:00
12:15
Ivivi Technologies, Inc.
Alcon, Inc.
Minnow Medical
Advanced Medical Optics, Inc.
NeoVista, Inc.
Kinetic Concepts, Inc.
Cardiovascular
ScyFIX
Stereotaxis, Inc.
Cytonome, Inc.
Deltex Medical Group plc
SyntheMed, Inc.
Sunshine Heart, Inc
Xthetix, Inc.
InnerPulse, Inc.
Johnson & Johnson – Ethicon, Inc.
Orqis Medical Corporation
Nitric Bio
Celleration, Inc.
TissueLink Medical, Inc.
Johnson & Johnson – DePuy
Orthopaedics
Small Bone Innovations, Inc.
Cardiovascular
11:00
Meridian DE
Diagnos
tics
10:45
Wound
Care
10:15
Care
10:00
OTC
09:45
Wound Care Skin
09:30
Orthopedics
09:15
Ortho
pedics
09:00
Ophthalmology
Meridian C
Acorn Cardiovascular, Inc.
Edwards Lifesciences
Cardium Therapeutics
MicroPhage, Inc.
Micronics, Inc.
02:00
Victhom Human Bionics
Aureon Laboratories
02:15
Neuronetics, Inc.
02:45
03:00
03:15
03:30
03:45
BeneChill
Nanomix, Inc.
GeneEx, Inc.
Nanospectra Biosciences, Inc.
Chembio Diagnostics Inc.
Seegene Inc.
NeoMatrix, LLC
GlucoLight Corporation
Reflectance Medical, Inc.
Imaging
02:30
Diagnostics
Advanced Liquid Logic
Additional Hot Sectors
Axial Biotech
01:45
CardioMag Imaging
Rockland Technimed Limited
Acorn Cardiovascular, Inc.
Mr. Rich Lunsford
President and CEO
New Brighton, Minnesota
United States
www.acorncv.com
2
Advanced Liquid Logic
Mr. Richard M. West
President and CEO
Research Triangle Park, North Carolina
United States
www.liquid-logic.com
Founded: 2004
Employees: 22
Mission / Background:
Advanced Liquid Logic was founded in 2004 as a technology spinout from Duke University's Pratt
School of Engineering following several years of technology development within Duke's electrical
engineering labs. The Company has developed significantly since then by licensing the core patents
from Duke, writing and winning multiple grants, initiating academic and commercial collaborations,
securing a first round of venture financing, filing additional patent applications, and building an
excellent team. The company is now making progress toward transitioning its technology into a
broadly-useful and highly differentiated diagnostic analyzer platform product. The Company has
demonstrated clinical chemistry, immunoassays, and PCR with sensitivity rivaling or exceeding clinical
laboratory instruments; DNA sequencing on chip is in development. The team's most recent test results
are impressive: real-time, quantitative PCR (genomic Candida DNA amplification) for 40 cycles in less
than 5 minutes - 7 seconds per cycle - and a highly sensitive immunoassay of Interleukin 6 in under 5
minutes. The twenty-person Company expects to launch its first commercial product into the research
instruments market in 2008.
Ownership: Private
Main Sector:
Subsectors:
Medical Technology
In vitro diagnostic devices
Product / Technology Summary:
Digital microfluidics allows fluid handling to be broken down into discrete fluid nanodroplets which are
electrically, programmably manipulated to dispense, transport, split, and mix fluids under computer
control. The platform is both reconfigurable and scalable, allowing many different types of assays to
be performed on a single general-purpose chip. Digital microfluidics has been developed through
multiple PhD theses by the principals and substantial funding over the last several years. The Company
is assembling a portfolio of patented design features to perform a diverse range of on-chip liquidhandling functions. Advanced Liquid Logic has secured the core intellectual property developed by
the co-founders while at Duke University in the form of an exclusive license of Duke's issued and
pending patents. In addition, the Company has aggressively expanded its IP portfolio through internal
filings and through the acquisition of Nanolytics, the Company's primary technology competitor. All
told the Company now has 4 issued patents and over 30 patents pending.
This technology has the potential to be “game-changing” with dozens of products in several multibillion dollar markets. Advanced Liquid Logic expects to be the first and only company to apply
droplet-based, digital microfluidics to solving problems in these markets. Early products will address
neonatal blood diagnostics, infectious disease detection, and chronic disease and therapy
management. A wide breadth of assay capability has already been implemented, including clinical
chemistry, immunoassays, and PCR, and DNA sequencing is in development. Significant synergies
among products will be achieved by applying similar control electronics, software, and chip
technology. The Company's first platform diagnostic product will be a bench top multifunction
analyzer. Current point-of-sample collection analyzers perform only one type of test; they do not have
3
the sophisticated liquid handling system that is required to perform multiple types of tests or extensive
panels of tests. In addition the Company envisions a very inexpensive PDA-like multifunction analyzer
that can take a single body fluid sample on a disposable cartridge and automatically perform any
liquid-based test. Advanced Liquid Logic expects that these cartridges, capable of a panel of
complex tests of multiple types will cost in the $1 to $2 range.
Collaborations:
The Company will address a broad set of needs for rapid testing for the medical and other industries. A
pre-IDE meeting with the FDA indicated that a 510K approval process is likely for most assay
implementations, which will facilitate relatively rapid deployment of a broad menu of tests. The
Company will be implementing existing assays on its inexpensive analyzer and low-cost disposable labon-a-chip. Advanced Liquid Logic will require licenses for some reagents and certain test processes in
order to implement the full range of existing tests.
In the short term the Company will continue to add to its pipeline of grant-funded research from NIH
and other Government agencies to advance the basic technology platform and to demonstrate
capability to solve a wide variety of important problems. The Company is preparing to launch a
laboratory analyzer for use by scientists that will be similar in form and function to later FDA-regulated
diagnostic products. In addition to developing its own products the Company seeks partnerships with
large companies to cooperatively develop and launch products; the Company expects to sell
products through either distributors or more comprehensive commercial partnerships. The Company is
currently in discussion with potential commercial partners for implementation of the technology in
various applications.
Product /
Technology
Digital microfluidic
immunoassay
research
instrument
Digital microfluidic
PCR research
instrument
Digital
microfluidics
4
Availability
Development
Phase
In development
In development
In development
Area
Technology Type
Development
In vitro diagnostic
devices
Medtech Product
Development
In vitro diagnostic
devices
Medtech Product
Clinical
Development
Tools
Technology
Advanced Medical Optics, Inc.
Ms. Jane Rady
Executive Vice President, Strategy & Corporate Development
Santa Ana, California 92705
United States
www.amo-inc.com
Founded: 2002
Employees: 4,200
Although we have been an independent company for only the past 5-years, our heritage goes back
nearly 50 years with eye care products that began in Allergan, American Hospital Supply and Chiron
Vision. We are dedicated to providing a broad-based offering of products for the patient and
practitioner to care for their vision needs throughout their life. Our over-arching objective can be
summed by our tag line, “Vision. for Life.” Capturing patients in their early teen years when they are
first in need of refractive correction, AMO provides c lens care products and eye drop products for the
contact lens wearer. As patient's age and refractive needs change, we provide a variety of products
for various life style needs. As the world leader in Corneal Refractive Surgery, we provide the most
comprehensive and medically state of the art LASIK. As patients age and become presbyopic (loss of
near vision accommodation of the natural lens), our products serve their needs with the most variety
and best correcting intra-ocular lenses ... multifocal IOLs for Presbyopia and monofocal/multifocal IOLs
for the cataract patient.
Ownership: Public
IPO: 2002
Ticker: EYE
Stock Exchange: NYSE
Main Sector:
Subsectors:
Medical Technology
Ophthalmic and optical devices
AMO develops advanced, life-improving vision technologies for people of all ages. Products in the
cataract/implant line include intraocular lenses (IOLs), phacoemulsification systems, viscoelastics, and
related products used in ocular surgery. AMO owns or has the rights to such product brands as
ReZoom®, Tecnis®, Clariflex®, Sensar®, and Verisyse® IOLs, Sovereign®, Sovereign® Compact and
WhiteStar Signature™ phacoemulsification systems with WhiteStar® technology, Healon® viscoelastics,
and the Baerveldt® glaucoma shunt. Products in the laser vision correction line include wavefront
diagnostic devices, femtosecond lasers and associated patient interface devices, and excimer laser
vision correction systems and treatment cards. AMO brands in the laser vision correction business
include Star S4 IR®, WaveScan Wavefront®, Advanced CustomVue™, IntraLase® FS, IntraLase
Method™ and IntraLasik®. Products in the contact lens care line include disinfecting solutions,
enzymatic cleaners and lens rewetting drops. Among the eye care product brands the company
possesses are COMPLETE®, COMPLETE® Blink-N-Clean®, Consept®F, Consept® 1 Step, Oxysept® 1
Step, UltraCare®, Ultrazyme®, Total Care™ and blink™ branded products.
Collaborations:
Alliance can take many forms depending upon our strategic needs and that of our partner. Over
these past five years we have entered into over 36 different arrangements that have included
distribution deals, product / technology licenses, co-development arrangements, equity positions and
the like with large and small companies, private as well as public entities, and universities and
5
government laboratories. We seek partnerships that benefit both entities and are flexible in the
structure to fit the needs. Terms can range from simple OEM agreements to more complicated
transactions involving equity, milestone payments and marketing rights.
Our areas of focus remain in the field of ophthalmology focusing on medical devices and
technologies, some of which can be fundamental advances in the science of lasers, materials, and
optics. We seek advances in medical therapy for both the anterior and posterior segment of the eye
(from the corneal to the retina / optic nerve).
Product /
Technology
Corneal Refractive
Surgery (LASIK)
Cataract
Refractive
Surgery,Glaucoma,
Eye Care Products
6
Availability
Development
Phase
Area
Technology Type
Ophthalmic and
optical devices
Medtech Product
Alcon, Inc.
Mr. Doug MacHatton
Vice President, Investor Relations and Corporate Communications
Fort Worth, Texas
United States
www.alcon.com
Founded: 1947
Employees: 13,000
Alcon, Inc. is the world's leading eye care company, with sales of $4.9 billion in 2006. Alcon, which has
been dedicated to the ophthalmic industry for 60 years, researches, develops, manufactures and
markets pharmaceuticals, surgical equipment and devices, contact lens care solutions and other
vision care products that treat diseases, disorders and other conditions of the eye. At Alcon we have
one mission: To discover, develop, produce and market innovative, high quality eye care products
that preserve, restore and enhance sight.
Ownership: Public
IPO: 2002
Ticker: ACL
Main Sector:
Subsectors:
Medical Technology
Alcon is a research and development-driven, global medical specialty company focused on eye
care. We develop, manufacture and market surgical equipment and devices, pharmaceuticals and
consumer vision care products to treat eye diseases and disorders. Our broad range of products
represents the strongest portfolio in the eye care industry. We have the largest commitment to
ophthalmic research and development of any company in the world. Currently, our products are sold
in over 180 countries, and we are present in every significant market in the world where eye care
professionals practice.
Collaborations:
Our alliances with innovative partners are an integral and essential part of our long term strategy.
Strong relationships with numerous partnering physicians, academia and industry-related organizations
strengthen our position as leaders in ophthalmic and optometric sciences, and provide us access to
leading surgical devices and compounds. Our licensing efforts with others invested in eye health have
led to several notable partnerships. We are honored to have the chance to produce such results with
other prestigious organizations. Alcon is always in search of source compounds, devices and
technology for evaluation by research and development.
7
Aureon Laboratories
Dr. Vijay Aggarwal
CEO and President
Yonkers, New York
United States
www.aureon.com
Founded: 2002
Aureon Laboratories is dedicated to improving healthcare and advancing personalized medicine by
commercializing predictive tests for cancer recurrence. Aureon believes that by integrating disease
pathology, biology, cutting edge computational tools, and proprietary statistical expertise, the
decision making process for treatment options and ultimately the quality of life for patients can be
improved.
Aureon's technology predicts individual clinical outcomes by interrogating and analyzing the tissue of
individual patients to provide the first comprehensive and fully integrated view of the disease process a systems pathology view. Aureon has developed a combination of proprietary systems pathology
technologies in the areas of protein multiplexing, imaging and bioinformatics.
Allied with major cancer centers and pharmaceutical companies, Aureon is focused on oncologybased clinical tests to assist physicians in developing appropriate treatment strategies for monitoring
patients with cancer. Aureon also supports bio-pharmaceutical companies to develop better
targeted therapeutics by attempting to predict patient outcome to specific treatments.
Ownership: Private
Main Sector:
Subsectors:
Biotechnology Instrumentation & Services
Diagnostic services
Provider of comprehensive services to validate biomarkers in tissue samples and build predictive assys
to determine theapeutic response and disease progression.
8
Axial Biotech
Mr. John Michael Climaco
President & CEO
Salt Lake City, Utah
United States
www.axialbiotech.com
Founded: 2003
Employees: 15
Axial is revolutionizing spine care by developing molecular diagnostics and motion preserving
technologies. Axial will transform treatment paradigms by using its predictive tests to bring motion
preserving technologies to the widest range of patients at the earliest appropriate stage.
Ownership: Private
Main Sector:
Subsectors:
Biotechnology
Genomics
Our first product is a genetic prognostic test for idiopathic scoliosis.
Collaborations:
We have a collaboration with DePuy Spine, a Johnson & Johnson Company, for the distribution of this
first product.
9
BeneChill
Dr. Denise Barbut
Founder, President & CEO
San Diego, California
United States
www.benechill.com
Founded: 2004
Employees: 15
Brain cooling techniques for protection during cardiac arrest, TBI and stroke
Ownership: Private
Main Sector:
Subsectors:
Medical Technology
Other
BeneChill's mission is to develop novel cooling technologies to improve patient outcomes after acute
ischemic events such as cardiac arrest, stroke, and traumatic brain injury.
The RhinoChill System has been developed as a means of initiating and providing therapeutic cooling
with limited delays. It is non-invasive, easy-to-use, portable, and requires no external power.
The RhinoChill technology overcomes limitations of other temperature reduction technologies limitations that prevent early and rapid initiation of patient cooling.
•
Surface cooling devices such as water-filled blankets and pads, while easy to apply, are
inefficient,cumbersome, require large refrigeration units and may interfere with patient
management.
•
Intravascular cooling devices which cool the blood, while more efficient than surface cooling
devices, are invasive, require large refrigeration units, and need to be placed by specially
trained physicians under restricted conditions. The invasive nature of these devices carry risks
of additional complications.
The RhinoChill System uses the nasal cavity for cooling. This is advantageous due to the nasal cavity
being:
•
A natural orifice into the body
•
In close proximity to the brain
•
A natural heat exchanger
Use of the nasal cavity enables treatment by non-specialized medical personnel using non-sterile
technique in any environment.
Collaborations:
Exploring corporate partnerships.
Product /
Technology
RhinoChill
10
Availability
Development
Phase
Area
Technology Type
n/a
Single use devices
Medtech Product
CardioMag Imaging, Inc.
Mr. Carl H. Rosner
CEO
Schenectady, New York
United States
www.cardiomag.com
Founded: 1999
CardioMag Imaging is dedicated to the application of advanced technologies and systems for the
rapid and accurate diagnosis of diseases, especially those affecting the heart, and delivering cost
saving equipment to healthcare providers.
Ownership: Private
Main Sector:
Subsectors:
Medical Technology
Other
The magnetocardiograph (MCG) is a device which detects, displays, and analyzes the magnetic
signals that originate from cardiac electric activity.
Collaborations:
Our sales and marketing efforts, including collaboration with first rank hospitals, such as Cedars Sinai
and the Mayo Clinic, have now laid the foundation for marketing to targeted U.S. and international
markets, fully supported by our planned distribution system.
11
Cardium Therapeutics
Mr. Christopher J. Reinhard
Chairman & CEO
United States
www.cardiumthx.com
Founded: 2003
Employees: 65
Cardium Therapeutics is a medical technology company primarily focused on the development and
commercialization of novel biologic therapeutics and medical devices for cardiovascular and
ischemic disease. Since we were initially funded in October 2005, we have made three strategic
acquisitions and assembled a portfolio of innovative late-stage cardiovascular and regenerative
medicine product candidates, together with medical devices having U.S. Food and Drug
Administration (“FDA”) clearances that are marketed and sold through our direct sales force. We have
established a pipeline of innovative products that are divided into three business units, Cardium
Biologics, InnerCool Therapies, and Tissue Repair Company.
Ownership: Public
IPO: 2005
Ticker: CXM
Stock Exchange: AMEX
Main Sector:
Subsectors:
Biotechnology
Gene Therapy
Biological therapeutics
Cardium Therapeutics is a medical technology company primarily focused on the development and
commercialization of novel biologic therapeutics and medical devices for cardiovascular and
ischemic disease. Since we were initially funded in October 2005, we have made three strategic
acquisitions and assembled a portfolio of innovative late-stage cardiovascular and regenerative
medicine product candidates, together with medical devices having U.S. Food and Drug
Administration (“FDA”) clearances that are marketed and sold through our direct sales force. We have
established a pipeline of innovative products that are divided into three business units, Cardium
Biologics, InnerCool Therapies, and Tissue Repair Company.
Collaborations:
Cardium Therapeutics was initially formed as a Delaware corporation in December 2003 by
Christopher J. Reinhard, Chairman, President and Chief Executive Officer, and Tyler M. Dylan, Ph.D.,
Chief Business Officer and General Counsel, to acquire certain technology and product rights from
Schering AG Group, Germany relating to certain growth factor therapeutics that were initially
developed by Collateral Therapeutics Inc. (“Collateral”) in partnership with Schering. Mr. Reinhard was
a co-founder and executive officer of Collateral and Dr. Dylan was General Counsel of Collateral. In
2002, following a six-year strategic research and development collaboration and successful Phase 2
clinical studies of Generx, Schering acquired Collateral for approximately $160 million.
As part of a strategic refocusing in 2004, Schering divested its cardiovascular small molecule drugs and
biologics under clinical development, including Generx. Mr. Reinhard and Dr. Dylan subsequently
negotiated a transaction to acquire Schering's portfolio of cardiovascular growth factor therapeutics
12
formally co-developed with Collateral. In October 2005, Cardium completed a private equity
financing concurrent with a merger transaction with a small public company raising $30 million to
support its acquisition of Schering's portfolio of growth factor therapeutics. Since Cardium was initially
funded, it has made three acquisitions:
In October 2005, Cardium acquired a portfolio of growth factor therapeutics from the Schering AG
Group, Germany, including the later-stage Phase 3 product candidate, Generx™, a DNA-based
growth factor therapeutic which is being developed for potential use by interventional cardiologists as
a one-time treatment to promote and stimulate the growth of collateral circulation in the hearts of
patients with ischemic conditions such as recurrent angina.
In March 2006, Cardium acquired the technologies and products of InnerCool Therapies, a San Diegobased medical technology company in the emerging field of temperature modulation therapy to
rapidly and controllably cool the body in order to reduce cell death and damage following acute
ischemic events such as cardiac arrest or stroke, and to potentially lessen or prevent associated
injuries such as adverse neurological outcomes.
In August 2006, Cardium acquired the technologies and products of the Tissue Repair Company (TRC),
a San Diego-based biopharmaceutical company focused on the development of growth factor
therapeutics for the treatment of severe chronic diabetic wounds. TRC's lead product candidate,
ExcellarateTM, is a DNA-activated collagen gel for topical treatment formulated with an adenovector
delivery carrier encoding human platelet-derived growth factor-BB (PDGF-BB). Excellarate is initially
being developed to be administered once or twice for the potential treatment of non-healing
diabetic foot ulcers. Other potential applications for TRC's Gene Activated Matrix™ (GAM)
technology include therapeutic angiogenesis (cardiovascular ischemia, peripheral arterial disease)
and orthopedic products, including hard tissue (bone) and soft tissue (ligament, tendon, cartilage)
repair.
Product /
Technology
CoolBlue and
RapidBlue
Temperature
Management
Systems
Excellarate
Generx
RapidBlue and
CoolBlue Systems
Availability
Development
Phase
Area
Technology Type
Technology
In development
Phase II
In development
Phase III
On the Market
Skin and
subcutaneous
tissue
Cardiovascular
Other
Biotech Product
Biotech Product
Medtech Product
13
Celleration, Inc.
Mr. Kevin Nickels
President & CEO
Eden Prairie, Minnesota
United States
www.celleration.com
Founded: 2001
Employees: 49
Celleration® Inc., a Minnesota based medical device company, has produced an impressive and
growing body of clinical research with an exciting new wound healing device, the MIST Therapy®
System. MIST Therapy is a painless non-contact ultrasound device that is easy to use with a short
treatment time. MIST Therapy promotes wound healing through cellular stimulation while removing
bacteria from the wound allowing clinicians to heal wounds faster.
Ownership: Private
Main Sector:
Subsectors:
Medical Technology
Wound Care
MIST Therapy System
14
Chembio Diagnostics, Inc.
Mr. Lawrence Siebert
President and Chief Exectuive Officer; Chairman of the Board
Medford, New York
United States
www.chembio.com
Founded: 1992
Employees: 100
Chembio develops, manufactures and sells products that serve the growing global rapid point of care
in vitro diagnostic testing market for infectious diseases and other conditions using both in-licensed
single path lateral flow technology and its new patented platform known as Dual Path Platform. The
Company operates an FDA Class III biologics, USDA and ISO 13.485 approved manufacturing facility in
Medford, NY. The Company is seeking to leverage its new DPP intellectual property with their expertise
in lateral flow technology, product development and regulated manufacturing and to develop
collaborations with premier organizations that have best in class sales, marketing and distribution
capabilities.
Ownership: Public
IPO: 2004
Ticker: CEMI
Stock Exchange: other
Main Sector:
Subsectors:
Medical Technology
The recently patented Dual Path Platform point of care lateral flow technology is creating multiple
new product development opportunities for the Company and its selected partners. The Company
currently manufactures three rapid HIV tests that serve the global market, including two that are FDA
approved and one that is CLIA waived. The company also developed and manufactures the only
rapid test for Chagas disease that has been employed in a nationwide screening program.
(Continued)
15
Collaborations:
Chembio's partnering strategy is to leverage our new DPP intellectual property with our expertise in
lateral flow technology, product development and regulated manufacturing, and to develop
collaborations with premier IVD organizations that have best in class sales, marketing and distribution
capabilities.
Product /
Technology
DPP Flu A/B
DPP Hepatitis C
DPP HIV 1/2
DPP Syphilis
Dual Path POCT
Immunoassay
Platform
16
Availability
Development
Phase
Available for outlicensing
In development
Development
Development
Development
Development
On the Market
Area
Technology Type
In vitro diagnostic
devices
In vitro diagnostic
devices
In vitro diagnostic
devices
In vitro diagnostic
devices
In vitro diagnostic
devices
Medtech Product
Medtech Product
Medtech Product
Medtech Product
Medtech Product
Cytonome, Inc.
Dr. Lydia Villa-Komaroff
Chief Executive Officer
Boston, Massachusetts
United States
www.cytonome.com
Founded: 2003
Employees: 25
Cytonome, Inc. has developed the Gigasort™ System, a revolutionary platform technology that will
transform cell therapy, facilitate new clinical trials and enable new medical treatments for a variety of
common medical conditions. Cytonome offers a state-of-the-art cell sorter that combines an ultrahigh throughput optical cell sorting system (the GigasortTM Instrument) with a single-use, sterile,
disposable cartridge (the GigasortTM Cartridge). It is the only optical sorter that allows the rapid, sterile
selection of human cells with multiple markers under cGMP conditions for clinical use. The Gigasort™
System enables advanced cell therapy clinical trials and patient treatments that are not possible with
technologies currently available to physicians. The Gigasort™ System will significantly improve
outcomes of bone marrow transplants (BMT), commonly used today to treat cancers of blood cells
(leukemias and lymphomas). Additionally, the Gigasort™ System will immediately enable clinical trials
and treatments for solid organ cancers, autoimmune diseases and tissue regeneration treatments for
cardiac disease, liver disease, diabetes and other illnesses.
Cytonome's mission is to provide technology to our customers to enable the development of novel cell
therapy protocols and treatments.
Ownership: Private
Main Sector:
Subsectors:
Medical Technology
Regenerative Medicine
Cytonome Inc. develops, manufactures, and markets clinical grade optical cell sorting technology.
Cytonome's Gigasort system is the only clinical grade, cGMP compliant optical cell sorter built around
a closed, sterile and disposable cartridge to guarantee operator safety and sample isolation.
Cytonome's revolutionary technology can be used for the precise and safe selection of discrete cell
subpopulations. Gigasort™ technology has been designed for use in cGMP cell production
environments where investigators wish to transition pre-clinical protocols to clinical production and
develop new cell therapy inventions. The Gigasort™ cell sorter will enable a broad array of cell and
gene therapies, including new treatments for cancer, autoimmune disease and regenerative
medicine applications.
Collaborations:
Cytonome wishes to develop partnerships and collaborations in multiple areas. We are interested in
locating strategic partners who wish to expand their portfolio of medical instrument technologies into
the clinical stem cell and cell therapy arena. This could include companies selling instrumentation into
oncology, autoimmune disease, cardiovascular, diabetes, hepatic disease, joint reconstruction,
wound healing and other markets with stem cell or cellular therapy initiatives. We are also seeking
strategic partnerships with companies that have developed other instrumentation used in clinical cell
processing, such as cord blood processing, apheresis, cell enrichment and other cell processing
technologies. Additionally, we are interested in collaborating with reagent development
17
organizations (or CRO / CMO organizations) with expertise in developing cGMP reagents and cell
products used in cellular medicine.
Product /
Technology
Cytonome
Gigasort
Technology
Gigasort
Instrument and
Cartridges
18
Availability
Development
Phase
Area
In development
Technology Type
Technology
Development
Regenerative
Medicine
Medtech Product
Deltex Medical Group plc
Mr. Andy Hill
Chief Executive
Chichester, West Sussex
United Kingdom
www.deltexmedical.com
Founded: 1982
Employees: 50
Deltex Medical's aim is to develop and market technologies that will establish Targeted Volume
Management (TVM) - the delivery of the right amount of the right fluid at the right time - as a standard
of care for all patients needing intravascular fluid management.
Ownership: Public
IPO: 2001
Ticker: DEMG
Stock Exchange: LSE
Main Sector:
Subsectors:
Medical Technology
Single use devices
Minimally invasive Esophageal Doppler monitoring system for real-time, beat to beat determination of
a variety of haemodynamic variables. Primarily used in the management and optmisation of
circulating blood volume. The monitor uses a disposable probe that is placed via the mouth or nose
into the patient's esophagus. The CardioQ has been demonstrated in seven randomised controlled
trials to reduce significantly complications and shorten hospital stay in patients undergoing major
surgery - about 5 million patients annually in the USA - and has been the subject of a recent AHRQ
technology assessment that lead CMS to grant national coverage for its use in the OR and in ICU.
Collaborations:
None in the USA. Having just been granted coverage for reimbursement of the use of the CardioQ for
fluid management and cardiac output determination in surgery and in ventilated patients in intensive
care, we are now seeking candidates to collaborate and partner with us in the USA. We are not
seeking a distribution deal, rather a strategic partnership.
Product /
Technology
CardioQ
Suprasternal
Doppler Monitor
Availability
In development
Development
Phase
Area
Technology Type
On the Market
Single use devices
Medtech Product
Development
Other
Medtech Product
19
Edwards Lifesciences
Mr. John H. Kehl
Corporate VP, Strategy & Business Development
Irvine, California
United States
www.edwards.com
Founded: 2000
Employees: 5,700
At Edwards Lifesciences, we are dedicated to providing innovative solutions for people fighting
cardiovascular disease.
Through our actions, we will become trusted partners with customers, colleagues, and patients creating a community unified in its mission to improve the quality of life around the world. Our results
will benefit customers, patients, employees, and shareholders.
We will celebrate our successes, thrive on discovery, and continually expand our boundaries. We will
act boldly, decisively, and with determination on behalf of people fighting cardiovascular disease.
Helping Patients is Our Life's Work, and Life is Now.
Ownership: Public
IPO: 2000
Ticker: EW
Main Sector:
Subsectors:
Medical Technology
Active implantable devices
Edwards Lifesciences leverages its design, development and marketing expertise through these
product categories:
Heart Valve Therapy
Edwards is the world's number-one heart valve company, including tissue replacement heart valves
and valve repair products, such as those marketed under the Carpentier-Edwards, Cosgrove-Edwards
and Edwards Prima Plus product brands. The company invests more than any other in the advanced
treatment of cardiovascular disease and is currently pursuing less-invasive, catheter-based
approaches to treat heart valve disease.
Transcatheter Valve Interventions
Edwards is the leader in the development of new, experimental technologies designed for the nonsurgical repair or replacement of heart valves. These transcatheter heart valve technologies would
allow clinicians to repair or replace heart valves through a catheter, eliminating the need for openheart surgery. While the products are currently in development, Edwards believes the technologies
hold a great deal of promise for many people who are not good candidates for surgery.
Critical Care
Edwards has been a world leader in this area for more than 30 years, developing the Swan-Ganz
brand line of hemodynamic monitoring devices for measuring heart pressure and output during
20
surgical procedures and in post-surgical intensive care settings. Additional critical care products
include advanced venous access products, antimicrobial catheters, disposable pressure transducers
and a blood-management protection system.
Cardiac Surgery
Edwards produces the Research Medical brand line of disposable cannulae used during
cardiopulmonary bypass and the EMBOL-X embolic management system for use during cardiac
surgeries.
Vascular Therapies
Edwards' vascular products include the Fogarty brand line of balloon-tipped catheters, LifeStent
peripheral stents, catheter-based products, surgical clips and inserts, and angioscopy equipment.
21
GeneEx, Inc.
Mr. Mead Michael McCabe
President & CFO
Hialeah, Florida
United States
www.geneexinc.com
Founded: 2003
Employees: 6
GeneEx is at the forefront of an emerging trend in medicine: the use of noninvasive and minimally
invasive techniques for diagnosis or prediction of disease. Using proprietary technology, GeneEx is
creating diagnostics for numerous infectious diseases, including periodontitis, group A strep and
systemic fungal infections.
Ownership: Private
Main Sector:
Subsectors:
Medical Technology
The Company's first product will be the Rapid Periodontitis Test (RPT): an inexpensive, chair-side saliva
test planned for launch by Q2 2008. Dentists will use the RPT to 1) screen patients for periodontal
disease, 2) measure treatment efficacy and 3) aid in patient compliance. GeneEx's RPT is a small,
disposable lateral flow test for use during routine dental examinations. The dentist or hygienist applies a
small saliva sample into the sample well of the test cartridge and if the patient has periodontal
disease, a colored test line will appear within minutes in the “results” window indicating a positive test
and a colored “control” line will appear in the same window indicating the test is working properly. If
the patient does not have periodontal disease, only the control line will appear.
GeneEx also plans to launch a saliva based, rapid antigen detection test for group A streptococcus
(GAS) to both professional and consumer (over the counter) markets. The test will be a saliva based
antibody test that detects active pathogenesis caused by GAS, not just the presence of GAS, so it will
help to reduce unnecessary prescription of antibiotics. GeneEx then plans to launch point of care tests
for deadly fungal infections to the professional market
Collaborations:
British Biocell International
GeneEx and British Biocell International (BBI) recently executed a collaboration agreement whereby
the companies plan to jointly develop a saliva test for strep throat targeted to the consumer over the
counter market.
University of Florida Dental School and Medical School
Members of GeneEx's Science Advisory Board are on the research and clinical staff of these schools
which is expected to keep the company engaged with cutting edge research in the dental and
diabetes market.
Synogen Development Group, LLC
Synogen Development Group, LLC (Synogen) is an early-stage investor in GeneEx. Synogen partners
with select early-stage biotech and med-tech companies, providing seed-stage financing as well as
assistance in regulatory affairs, intellectual property issues, strategic planning, financial forecasting,
22
market research and management. With more than 20 associates who are experts in their fields, they
bring many years of experience and success in medical technology development and
commercialization. Synogen's focus is on bringing technologies to market rapidly, gaining regulatory
approval quickly, and producing profitable operations at the earliest stage possible in company
development.
BioQuest Corporation
BioQuest is a biotechnology development and regulatory consulting firm specializing in cost effective
strategic planning, development and commercialization of Biopharmaceutical and Biomedical
products and devices.
Product /
Technology
Availability
Development
Phase
Group A Strep Test
In development
Development
Rapid Periodontal
Test
In development
Development
Area
Technology Type
In vitro diagnostic
devices
In vitro diagnostic
devices
Medtech Product
Medtech Product
23
GlucoLight Corporation
Mr. Ray Krauss
President & CEO
Bethlehem, Pennsylvania
United States
www.glucolight.com
Founded: 2003
Employees: 15
GlucoLight is addressing the need for continuous non-invasive bedside glucose monitoring in the
hospital environment. The company's development and clinical testing of a reliable, accurate noninvasive continuous glucose monitor is progressing quickly, with pivotal FDA trials expected in late 2008.
The successful commercialization of GlucoLight's technology will enable the implementation of tight
glycemic control in the surgical, post-surgical and step-down units, which has been shown to reduce
patient mortality and morbidity and ultimately save lives. Once we initiate the FDA pivotal trial,
GlucoLight will accelerate development of a device suitable for the consumer market.
Ownership: Private
Main Sector:
Subsectors:
Medical Technology
Single use devices
Diagnostic and therapeutic radiation devices
Reusable instruments
Hospital Hardware
Collaborations:
GlucoLight intends to penetrate the hospital market by partnering with medical technology
companies with an established market presence and existing sales channels to support product
launch and ongoing marketing initiatives. Success in the acute care sector will support the company's
eventual entry into the $6+ billion consumer market. Several companies are actively engaged in
discussions with GlucoLight about potential partnership opportunities.
Product /
Technology
SENTRIS 100
SENTRIS 100
24
Availability
In development
Development
Phase
Area
Technology Type
Development
Hospital Hardware
Medtech Product
Technology
InnerPulse, Inc.
Mr. Daniel A. Pelak
President and CEO
Research Triangle Park, North Carolina
United States
www.inner-pulse.com
Founded: 2003
Employees: 42
Pioneering the develpment and commercialization of a novel implantable defibrillator and
pacemaker.
Ownership: Private
Main Sector:
Subsectors:
Medical Technology
InnerPulse is pioneering a minimally invasive approach to Cardiac Rhythm Managemant through the
development of devices that reside entirely within the vascular system of the body. All the workings of
a defibrillator have been miniaturized into a catheter type device.
Collaborations:
Independent privately held company.
25
Ivivi Technologies, Inc.
Mr. David Saloff
President and Co-CEO
Northvale, New Jersey
United States
www.ivivitechnologies.com
Founded: 2004
Employees: 16
Ivivi Technologies is a medical technology firm that innovates electrotherapies that are designed a
priori to improve specific electrochemical processes underlying known biochemical pathways, to
produce therapeutic effects in a wide range of inflammatory conditions.
Ownership: Public
IPO: 2006
Ticker: II
Stock Exchange: AMEX
Main Sector:
Subsectors:
Medical Technology
Regenerative Medicine
Ivivi's current proprietary electrotherapies utilize specifically tuned pulsed electromagnetic fields
(PEMF) to accelerate the endogenous anti-inflammatory physiology by accelerating a key binding
process at the beginning of the anti-inflammatory cascade. The FDA-cleared technology is based, in
part, on bone growth stimulator technology and is supported by a significant amount of published
data, ongoing sales and clinical use in wound care (Medicare approved) and in post-cosmetic
surgery. Ivivi is currently involved in human clinical trials treating end-stage cardiovascular disease at
the Cleveland Clinic and in animal trials in neurodegenerative disooders.
Collaborations:
Ivivi develops and validates therapies for specific medical specialties and actively seeks strategic
marketing partners. The Company has secured a world-wide exclusive distribution agreement with
Allergan, Inc (AGN), for the post-surgical control of pain and edema. The company is actively in
discussions with partners for the osteoarthritic and musculoskelatal pain markets, renal markets, wound
care and orthopedic markets. The company is seeking partners in the cardiovascular and
neurological areas, among others.
Product /
Technology
Positano
Roma
Taormina
26
Availability
Development
Phase
On the Market
On the Market
Development
Area
Technology Type
Regenerative
Medicine
Wound Care
Medtech Product
Regenerative
Medicine
Medtech Product
Medtech Product
Johnson & Johnson – DePuy Orthopaedics
Mr. Tom Oberhausen
Vice President, Business Development
Warsaw, Indiana
United States
www.jnj.com
Founded: 1886
Employees: 120,000
Ticker: JNJ
Main Sector:
Subsectors:
Medical Devices
Orthopaedics
27
Johnson & Johnson – Ethicon, Inc.
Ms. Susan Morano
Vice President, Business Development
Somerville, New Jersey
United States
www.jnj.com
Founded: 1886
Employees: 120,000
Ticker: JNJ
Main Sector:
Subsectors:
28
Medical Devices
Wound Management
Kinetic Concepts, Inc.
Ms. Catherine Burzik
President & CEO
San Antonio, Texas
United States
www.kci1.com
Founded: 1976
Employees: 6300
Kinetic Concepts, Inc. is a global medical technology company with leadership positions in advanced
wound care and therapeutic surfaces. We design, manufacture, market and service a wide range of
proprietary products that can improve clinical outcomes and can help reduce the overall cost of
patient care. Our Advanced wound-care systems incorporate our proprietary Vacuum Assisted
Closure, or V.A.C. Therapy technology, which has been demonstrated clinically to help promote
wound healing through unique mechanisms of action and can help reduce the cost of treating
patients with serious wounds.
Ownership: Public
IPO: 2004
Ticker: KCI
Main Sector:
Subsectors:
Medical Technology
Wound Care
V.A.C. Therapy
Therapeutic Surfaces
29
Micronics, Inc.
Ms. Karen Hedine
President & CEO
Redmond, Washington
United States
www.micronics.net
Founded: 1996
Employees: 20
Micronics' mission is to advance the development of a family of rapid molecular diagnostics for
infectious disease testing that are easy to use, highly accurate & deliver results in minutes where and
when most useful. The Company believes its products are responsive to unmet global health needs in
general with emphasis on solutions for the developing world.
Ownership: Private
Main Sector:
Subsectors:
Medical Technology
Micronics, Inc. (“Micronics” or the “Company”) is developing first-in-class, near patient point of care
(“POC”) molecular diagnostic tests that permit the decentralization of medical testing and vastly
improve infectious disease diagnostic outcomes. The Company's products are poised to transform the
diagnostics industry by enabling relatively unskilled users to rapidly and accurately perform the same
types of complex tests that today require hours to days to obtain a result when performed by skilled
personnel in large, multimillion dollar centralized laboratories. Micronics' products rely on its patented
technology platform that permits integration of numerous laboratory testing procedures into a
disposable, laboratory-on-a-card (“lab card”) device to deliver sample-to-result analyses in minutes at
the point of patient-caregiver contact. These products provide superior outcomes both in their ease of
use and accuracy, and are expected to generate new revenue streams for physician office testing for
an initial capital outlay of under $2,000.
Collaborations:
Micronics controls an important intellectual property platform that is broadly enabling across the
diagnostics sector. As such, the Company has and continues to employ a threefold strategy to
monetize its IP and advance products based on its technology. This involves 1) exclusive out-licensing
of target applications, 2) collaborating on product development with others in which Micronics retains
the commercial product rights, and 3) granting non-exclusive licenses for certain applications to which
Micronics retains the right to advance its own products in the same field of use.
Examples of the 1st alliance strategy are deCode Biostructures and Cleveland Biosystems. In the
second example, Micronics is collaborating with researchers at the University of Washington, PATH and
Nanogen for the advancement of a molecular/immunodiagnostic platform under funding from the Bill
and Melinda Gates Foundation. In the third scenario, Micronics has granted licenses to Honeywell and
Beckman Coulter.
For Micronics' products in development at this time, the Company has determined that the optimal
means to achieve broadest distribution both geographically and within its targeted market segments
(physician office, ER, hospitals) is via established distribution networks and global partnerships that
have the infrastructure and experience for successful product warehousing, supply, and customer
30
support. Micronics has initiated discussions with potential strategic partners and distributors worldwide.
Management has considerable experience in establishing product distribution and alliance networks
worldwide. To date the Company has initated active discussions with partners / distributors in China,
India, EU and South Africa.
Product /
Technology
ABO/Rh Card
DEC (Disposable
Enterics Card)
Microfluidics
Rapid Onset Fever
Panel
Availability
In development
Development
Phase
Area
Technology Type
Development
Single use devices
Medtech Product
Development
In vitro diagnostic
devices
Clinical
Development
Tools
In vitro diagnostic
devices
Medtech Product
In development
Development
Technology
Medtech Product
31
MicroPhage, Inc.
Mr. John H. Wheeler
Founder, VP, Business Development
Longmont, Colorado
United States
www.microphage.com
Founded: 2002
Employees: 11
MicroPhage is dedicated to improve health worldwide through development and marketing of rapid
bacterial identification and antimicrobial susceptibility testing products.
Ownership: Private
Main Sector:
Subsectors:
Medical Technology
MicroPhage has a proprietary amplification technology that enables rapid identificaion and antibiotic
susceptibility and resistance testing of bacteria direct from clinical, environmnetal, veterinary, and
industrial samples.
The company's platform technology, bacteriophage amplification, allows for rapid, non-molecular
bacterial testing, enabling high performance results in an easy-to-use test kit format.
Currently the company is focused on clinical products for the identification and antimicrobial
susceptibility and resistance testing of Staphylococcus aureus, including MRSA direct from blood
culture and nasal swabs.
Collaborations:
MicroPhage intends to partner with market partners to access domestic and international hospital,
reference laboratory, and primary care testing markets. MicroPhage will allow for a mix of OEM and
distribution partnerships in these markets.
Product /
Technology
Antibiotic
Susceptibility Test
platform
Bacterial ID
Technology
MRSA Screening
Test
S. aureus ID /
MRSA Blood
Culture
S. aureus ID Test
32
Availability
Development
Phase
Area
Technology Type
Development
In vitro diagnostic
devices
Medtech Product
Development
In vitro diagnostic
devices
In vitro diagnostic
devices
In vitro diagnostic
devices
Medtech Product
Development
In vitro diagnostic
devices
Medtech Product
Development
Development
Medtech Product
Medtech Product
Minnow Medical
Mr. Tom Steinke
CEO
United States
www.minnowmedical.com
Founded: 2003
Employees: 15
The Company has developed a proprietary catheter technology that enlarges narrowed body
lumens. The Company is actively pursuing the treatment of artery disease, seeking regulatory approval
first for use in peripheral arteries.
Ownership: Private
Main Sector:
Subsectors:
Medical Technology
Single use devices
Electro mechanical medical devices
The first product combines energy delivery with angioplasty that results in immediate and substantial
artery thru-lumen opening to increase blood flow. This fast but durable process could potentially
replace the need for vascular stents.
Collaborations:
Seeking sales and distribution partner.
Product /
Technology
GRST-Guided ReShaping
Technology
Minnow Catheter
Carotid
Minnow Catheter
Cerebral
Minnow Catheter
Coronary
Minnow Catheter
Nonvascular
Minnow Catheter
Other Vascular
Minnow Catheter
Peripheral
Availability
Development
Phase
Area
Available
licensing
Available
licensing
Available
licensing
Available
licensing
Available
licensing
Available
licensing
Technology Type
Technology
for out-
Development
Single use devices
Medtech Product
for out-
Development
Single use devices
Medtech Product
for out-
Development
Single use devices
Medtech Product
for out-
Development
Single use devices
Medtech Product
for out-
Development
Single use devices
Medtech Product
for out-
Development
Single use devices
Medtech Product
33
Nanomix, Inc.
Mr. Bill A. Perry
VP Sales, Marketing, & Business Development
Emeryville, California
United States
www.nano.com
Founded: 2000
Employees: 25
Nanomix is a leading nanoelectronic detection company launching detection devices based on
Sensation™ technology. These scaleable devices use ultra-sensitive carbon nanotube detection
elements combined with proprietary chemistries. They can be deployed across high value respiratory
and biodetection applications where low power consumption, small size, and ultra-sensitivity offer
significant performance advantages and enable unprecedented access to critical information.
Nanomix is pursuing product lines in 3 categories:
•
•
•
Biomolecule Devices
Respiratory Devices
NanoTect™ Monitors
Ownership: Private
Main Sector:
Medical Technology
Nanomix is a leading nanoelectronic detection company launching detection devices based on
Sensation™ technology. These scaleable devices use ultra-sensitive carbon nanotube detection
elements combined with proprietary chemistries. They can be deployed across high value respiratory
and biodetection applications where low power consumption, small size, and ultra sensitivity offer
significant performance advantages and enable unprecedented access to critical information.
Direct electronic detection of analytes eliminates the need for optical detection technologies that are
expensive, complicated, difficult to use and laboratory based. Sensation uses a random network of
carbon nanotubes - not individually selected and manipulated nanostructures - so the platform is
scalable to high volumes.
The Sensation platform will simplify and expand the use of biomolecule analysis through easy-to-use
handheld product configurations that may be used at the point of care. This platform has been used
to perform single base-pair mismatch detection of DNA SNPs in genomic samples. Applications
include molecular diagnostics of infectious diseases, and detection of biomarkers in personalized
medicine. Detection of protein models may aid in the diagnosis of conditions such as stroke or heart
attack, fertility/pregnancy tracking, and more. In the respiratory area, Sensation is enabling devices for
asthma monitoring and emergency airway management.
34
Collaborations:
Business development initiatives are pursued in a variety of forms, seeking to leverage the strengths of
each partner in order to bring devices to market most effectively. These include academic affiliations,
third party distribution agreements, sponsored development and revenue sharing deals, licensing
relationships, and platform sales.
Product /
Technology
Biomolecule
Products
NanoTect
Monitors
Respiratory
Products
Sensation
Availability
Development
Phase
In development
Development
In development
Area
Technology Type
In vitro diagnostic
devices
Medtech Product
Technology
Development
On the Market
In vitro diagnostic
devices
In vitro diagnostic
devices
Medtech Product
Medtech Product
35
Nanospectra Biosciences, Inc.
Mr. J. Donald Payne
CEO
Houston, Texas
United States
www.nanospectra.com
Founded: 2001
Employees: 14
Nanospectra has filed an IDE to commence a clinical trial of AuroLase(TM) therapy for the photothermal ablation of solid tumors. While applicable to virtually all solid tumors, the first application of
AuroLase Therapy will be in head and neck cancers. AuroLase Therapy is enabled by a new class of
optically tunable materials exclusively licensed from Rice University.
Ownership: Private
Main Sector:
Subsectors:
Medical Technology
Other
Delivery
AuroLase Therapy for the particle-based thermal ablation of solid tumors. An IDE has been filed to
commence a human trial in head and neck cancers.
Collaborations:
Collaboartive development of clinical applications in other solid tumors.
Product /
Technology
AuroLase Therapy
AuroShell Particles
36
Availability
In development
Development
Phase
Development
Area
Technology Type
Other
Drug
delivery/formulation
technology
Medtech Product
Technology
NeoMatrix, LLC
Mr. Paul Joseph Fitzpatrick
CEO
Irvine, California 92618
United States
www.neomatrix.com
Founded: 2000
Employees: 26
NeoMatrix is the manufacturer of the patented HALO™ Breast Pap test, the only 5 minute, fullyautomated, noninvasive breast cancer risk screening technology on the market. The HALO is
approved by the FDA for the collection of nipple aspirate fluid (NAF) for cytological evaluation. The
NAF can be used in the determination and/or differentiation of normal versus pre-malignant versus
malignant cells. The HALO is designed for use in the primary care setting as a part of a woman's annual
OB-GYN visit. The company believes that the adoption of the HALO system as a standard of care can
lead to significantly earlier breast cancer detection and a reduction in mortality from the disease,
similar to the reduction accompanied by the advent of the Pap test for cervical cancer.
Ownership: Private
Main Sector:
Subsectors:
Medical Technology
The HALO Breast Pap Test system looks for the presence of nipple aspirate fluid (NAF) and enables the
non-invasive expression of NAF from the breasts of non-lactating women during their well-woman visits
in 5 minutes. The samples can be analyzed for Atypical Ductal Hyperplasia (ADH), a well established
bio-marker that confers a 400% - 500% increased risk of developing breast cancer, using the same
cytological evaluation protocols as cervical cancer. The HALO system consists of reusable hardware
and disposable collection equipment.
Collaborations:
We are interested in partnering with companies that can help to advance the visability, adoption and
sales of the Halo Breast Pap System.
Product /
Technology
Disposable
Sample Collection
Cups NAFCUPS-01
HALO Cart
NAFCART-01
HALO CONSOLE
NAFD-100
HALO Patient
Interface Cassette
NAFCASS-01
Availability
Development
Phase
Area
Technology Type
On the Market
Other
Medtech Product
On the Market
In vitro diagnostic
devices
In vitro diagnostic
devices
Other
Medtech Product
On the Market
On the Market
Medtech Product
Medtech Product
37
NeoVista, Inc.
Mr. Tony Moses
Vice President, Marketing & Sales
Fremont, California
United States
www.neovistainc.com
Founded: 2005
Employees: 20
NeoVista, Inc. is a development stage medical device company working towards commercialization
of its proprietary technology utilizing intraocular epiretinal for the treatment of Wet Age-Related
Macular Degeneration (AMD).
Ownership: Private
Main Sector:
Subsectors:
Medical Technology
NeoVista, Inc. is developing a product line for the treatment of Wet Age-Related Macular
Degeneration. The first generation system consists of a reusable delivery device that emits strontium-90
beta radiation directly to the leaking vessels in the retina utilizing an epiretinal delivery approach.
The company is currently developing its next generation system, which will provide both reusable and
single-use components.
Product /
Technology
Epi-Rad90
Ophthalmic
System
Epi-Rad90
Ophthalmic
System
38
Availability
Development
Phase
In development
Development
In development
Area
Technology Type
Ophthalmic and
optical devices
Medtech Product
Discovery Tools
Technology
Neuronetics, Inc.
Mark Bausinger
Chief Financial Officer
Malvern, Pennsylvania
United States
www.neuronetics.com
Founded: 2003
Employees: 25
Neuronetics, Inc. is a medical device company focused on developing non-invasive therapies for
psychiatric and neurological disorders using MRI-strength magnetic field pulses. Based in Malvern, PA.,
Neuronetics is the leader in the development of TMS TherapyTM, a non-invasive form of
neuromodulation. The Company's lead product, NeuroStar TMS Therapy, is currently pending
clearance by the FDA for the treatment of depression. Neuronetics is preparing for a U.S. product
launch later in 2007.
Ownership: Private
Main Sector:
Subsectors:
Medical Technology
Electro mechanical medical devices
NeuroStar TMS Therapy is a non-invasive procedure using a novel medical device for the treatment of
major depressive disorder. Operated in a psychiatrist's office, the NeuroStar system delivers highly
focused MRI-strength magnetic field pulses that stimulate neurons in the brain that are linked to
depression. NeuroStar TMS Therapy can easily be performed as an outpatient procedure and does not
require anesthesia or sedation. Patients remain awake and alert during the procedure.
NeuroStar TMS Therapy was studied in a six-week randomized, sham (placebo)-controlled, triple blinded, monotherapy clinical trial. This trial consisted of 301 patients who were suffering from major
depression and who had not benefited from previous antidepressant medication therapy. The study
was conducted at leading research institutions across the United States, Canada and Australia.
NeuroStar TMS Therapy treated-patients had statistically significant response and remission rates that
were approximately twice the rate of sham-treated patients. The discontinuation rate due to side
effects was less than five percent.
NeuroStar TMS Therapy is currently pending clearance by the FDA and should be commercially
available in 2007. Neuronetics is building a direct sales and marketing team to launch NeuroStar in the
U.S. later this year.
Product /
Technology
NeuroStar TMS
Therapy
Availability
Development
Phase
In development
n/a
Area
Technology Type
Electro
mechanical
medical devices
Medtech Product
39
Nitric Bio
Mr. Frank J McCaney
CEO
Bristol, Pennsylvania
United States
www.nitricbio.com
Founded: 2006
Employees: 10
Nitric Bio was founded in late 2005 to commercialize a proprietary drug/device platform that utilizes
nitric oxide (NO) gas to treat topical diseases. Nitric Bio has exclusively licensed a critical patent estate
that covers the use of NO gas in all topical human applications. The company is initially developing
products to treat chronic wounds and topical infections. Clinical trials are underway in these disease
areas. Preliminary clinical studies have yielded positive outcomes in each case. More robust Phase II
trials are underway, with results anticipated in the coming months. Other potential applications
include products to treat other dermatologic conditions such as acne and psoriasis. The company has
received $14M in financing from two life science venture funds - Quaker BioVentures and New Spring
Capital.
NO is a well studied molecule with compelling therapeutic properties, including broad spectrum
antimicrobial activity and potent anti-inflammatory properties. The precise application of NO gas
allows for consistent and accurate delivery of the desired concentration of active agent.
The company has extensively studied the antimicrobial action of gaseous NO. In vitro studies under
GLP conditions demonstrate that NO gas effectively kills every bacteria studied (over 40 strains),
including several drug resistant species. In addition, work done in conjunction with the Center for
Biofilm Engineering in Montana has shown NO gas effectively kills bacteria while also eradicating
complicated biofilms. Chronic wounds often fail to heal because the wound is “stuck” in an
inflammatory state and with bacterial colonization and biofilm. NO gas addresses all of these issues.
Superphysiologic levels of NO gas kill infectious bacteria without harming human tissue and dampens
the inflammatory state. .
Ownership: Private
Main Sector:
Subsectors:
Pharma
Biological therapeutics
Our system is a drug/device combination. Depending on the application, NO gas can be delivered in
one of two venues. For short term use, the gas can be delivered from a small disposable can through
a catheter to a dressing that covers the wound or treatment area. For longer term use, the gas is
concentrated in a cylinder that is resident within a device which blends the gas with air prior to being
delivered through the catheter to a dressing. For chronic wounds, most treatment has been for 14
days at 8 hours per night. For antimicrobial use, the treatment is for a matter of hours or possibly
minutes, depending on the concentration utilized.
(Continued)
40
Collaborations:
Nitric Bio's management team has a long history in the chronic wound and topical disease fields. We
have strong affiliations with the wound care community, both in the academic setting and in industry.
Our last KOL meeting attracted the best of the best in wound care doctors. We expect to pursue
commercial partnerships in 2008.
Product /
Technology
gNOx
gNOx-D
gNOx-I
Availability
Development
Phase
Area
Technology Type
Development
Development
Development
Wound Care
Other
Other
Medtech Product
Medtech Product
Medtech Product
41
Orqis Medical Corporation
Mr. Kenneth Charhut
President & CEO
Lake Forest, California
United States
www.orqis.com
Founded: 1997
Employees: 35
Redefine heart failure therapy by developing devices that prevent or reverse the underlying disease
progression to increase treatment options available to the clinical community and improve patient
outcomes and quality of life.
Ownership: Private
Main Sector:
Subsectors:
Medical Technology
Single use devices
Orqis Medical has developed a platform technology that delivers continuous aortic flow
augmentation (CAFA) to assist the heart's ability to push blood through the arteries by pumping a
continuous stream of blood into the descending aorta. Early clinical study suggests that patients who
receive CAFA have reduced systemic vascular resistance, increased cardiac output and reduced
cardiac load.
Product /
Technology
Availability
CAFA
In development
Cancion System
Exeleras System
In development
In development
42
Development
Phase
Clinical
Development
Tools
Development
Development
Area
Technology Type
Technology
Single use devices
Active
implantable
devices
Medtech Product
Medtech Product
Reflectance Medical Inc.
Dr. Babs Soller
President
Northboro, Massachusetts
United States
www.reflectancemedical.com
Founded: 2007
Employees: 4
Reflectance Medical Inc. is an early stage company developing new technology to revolutionize the
care of patients with sepsis. The company's CareGuide Monitor noninvasively determines and displays
key parameters for early diagnosis of sepsis, a proven strategy for saving lives. CareGuide continuously
and quantitatively displays levels of microvascular oxygen, pH and hematocrit to provide treatment
goals to assure rapid and successful reversal of microvascular abnormalities associated with the
progression of sepsis.
Ownership: Private
Main Sector:
Subsectors:
Medical Technology
Single use devices
Hospital Hardware
Our product is a portable diagnostic monitor with a disposable noninvasive single patient sensor that
can provide quantitiative parameters for early detection of sepsis and targets to direct treatment.
Collaborations:
Research conducted at University of Massachusetts Medical School; manufacturing through ISO
certified/FDA registered OEM; research collaborations with US Army and NASA. Seeking corporate
marketing partners and investors.
Product /
Technology
CareGuide
Monitor
Availability
Development
Phase
Area
Technology Type
In development
Development
Single use devices
Medtech Product
43
Rockland Technimed Limited
Mr. Pradeep M. Gupte
Founder & CEO
Airmont, New York
United States
www.technimed.com
Founded: 1999
Employees: 10
Mission/Background:
Develop and market Contrast media, namely "Molecular Imaging Agent of Oxygen Metabolism for
Realtime Non-Invasive InViVo Monitoring" at the cellular level, with a resolution of 1 mm, using a
standard Magentic Resonance Imager, of biological subjects.
Oxy-17® is our "Contrast Media" product line for either Inhalation or as an injectable ( IV) & (IA)
applications. OxyMaps™ is software giving pictorial rendering in 2D & 3D showing Tissue with different
Oxygen Uptake Rate Zones in the context of its surrounding anatomy.
Oxy-17® and OxyMaps™ are useful as "Non Invasive Realtime Tissue Stress Monitor" to evaluate normal
and abnormal Oxygen Consumption rates in a biological subject, without any limitations on repeating
the test due to dosage and/or other limitations.
This is Platform Technology for "InViVo Realtime Tissue Viability Imaging" and is protected by issued and
registered Intellectual Property in 95% of the world markets for MRI Imaging.
The company has the world’s largest production source of materials secured that comprises Oxy-17® ,
for medical imaging. The target customers are hospitals, HMO's, PPO's and free standing Imaging
clinics. The potential to increase the overall demand for diagnostic, preventive and follow-up
screening is significant in this latent application sector. We will use strategic marketing partners to
satisfy this demand.
Pharmaceutical and Biotechnology/medical device companies
Note Oxy-17® is a registered Trade Mark of Rockland Technimed Ltd for: Oxygen-based diagnostic
agents, preparations and substances for medical purposes, namely, contrast media for medical
imaging for use with MRI diagnostic apparatus, and diagnostic scanning agents in the nature of
contrast media for use in In-Vivo imaging.
Ownership: Private
Main Sector:
Subsectors:
Biotechnology related
Other
Product and Technology Summary:
Early detection of ischemic injury, though difficult to achieve is becoming increasingly critical to the
proper utilization of new therapeutic intervention. Experts note that although Magnetic Resonance
angiography provides flow information and can image the blockage structure, the method cannot
characterize tissue damage. Rockland Technimed's patented Tissue Viability Imaging Agent provides
the missing link and critical test in assessing the quality and function of the underlying tissue. It can
differentiate between reversible or irreversible tissue injury. It provides the measurement of Oxygen
Extraction Fraction/Rate which is only possible using PET/CT with radioisotopes today.
44
The new patented technology is based on the normal process of cellular regeneration of adenosine
triphosphate with concomitant conversion of oxygen to water. Oxy-17® is formulated using a stable,
non radioactive isotope of Oxygen, can be used to detect hypoxic, but still viable tissue. After Oxy17® is absorbed by the cell and converted to water it perturbs the proton signal and creates a
negative contrast on the MRI. Each injury zone has a different rate of oxygen uptake so each zone
can be differentiated using MRI. Oxygen-starved hypoxic tissue consumes a larger percentage of
oxygen than normal tissue while nonviable (necrotic) tissue will not take up the Oxy-17 and will not
produce any water with it. It is like an early warning radar of tissue injury.
Conventional ( T2 or spin-spin relaxation weighted) MRI used with this technique, can detect the
difference between areas that contain water with O-17 and water with O-16, regions that are hypoxic
but viable can be distinguished from regions in which cell death has occurred. Oxy-17® can cross an
intact blood brain barrier, thus rendering this an ideal technique for brain imaging. Gadolinium or iron
oxide based contrast agents can not cross the INTACT blood brain barrier More than 38% contrast is
observed between the normal control image and an image after a bolus venous injection of the Oxy17
Oxy-17® is formulated using a naturally occuring stable non radioactive component of air to which all
living cells have been exposed and have used since the evolution of life on this planet Earth, therby
assuring patient safety.
Rockland Technimed believes that the Oxy-17® may prove useful for imaging the areas of ischemia or
reperfusion like myocardial ischemia, stroke and abdominal viceral ischemic injury. Other potential
uses for future investigation include mapping the epicenter in epilepsy, categorizing tumor
oxygenation, cancer staging, and assessing the eficacy of radiation and chemotherapy.
Collaborations:
Establish a strategic alliances with established marketing partners, in each of the major global
geographic markets, and launch product sales. Develop the latent global market sector of Oxygen
Metabolism Imaging to $750-$950 million sales by the fifth year of product introduction. Establish rapid
high growth rates per year during the first ten years of this operation.
Product /
Technology
OxyCart(TM) with
Oxynator(TM)
Oxy-17(R)
Tissue Viability
Imaging Agent
Availability
Development
Phase
Area
Technology Type
On the Market
Single use devices
Medtech Product
NDA
Cardiovascular
Biotech Product
Discovery Tools
Technology
45
ScyFIX
Mr. Thomas Harold
CEO/Founder
Chanhassen, Minnesota
United States
www.scyfix.com
Founded: 2002
Mission/Background:
To provide sight saving relief for people suffering from degenerative eye diseases to which there are
currently no cures or therapies.
Ownership: Private
Main Sector:
Medical Technology
Product and Technology Summary:
CE Mark ScyFIX 600
ScyFIX 650 (currently in FDA clinical trials)
Seegene, Inc.
Dr. Jong-Yoon Chun
Founder & CEO
Rockville, Maryland
United States
www.seegene.com
Founded: 2000
Employees: 45
Seegene, Inc. is a company specializing in molecular diagnostics and research applications. It novel
detection platform, "Seeplex®", sets a new standard in high-throughput and simultaneous multipathogen detection - or "multiplexing" - for the molecular diagnostics market. Seeplex® technology
accurately detects multi-pathogens with high-throughput speed, ultimately providing the most
economical basis for saving time, labor and cost. Our mission is to leverage our diagnostic testing
technology platform to become a leader in molecular diagnostics for infectious diseases, genetic
disorder detection, and drug resistant detection.
Ownership: Private
Main Sector:
Biotechnology
Seeplex® line of molecular diagnostics kits are based on Seegene's multiplex PCR technology using
our proprietary Dual Priming Oligonuclrotide (DPO™) technology. DPO™ results in greatly improved
PCR specificity with no false positives, thereby delivering the industry's most accurate, rapid and cost
effective testing method for 1) genetics & pharmacogenetics, 2) infectious diseases, and 3) oncology
& chromosomal analysis.
46
Collaborations:
1. Strategic partnership
We are looking to form strategic partnerships with molecular diagnostic companies or instrument
companies.
2. OEM business
We are seeking OEM business opportunities with molecular diagnostic companies or instrument
companies for the range of our Seeplex® products.
3. Outsourcing for development
We are looking to provide product development services to molecular diagnostic companies,
pharmaceutical companies or instrument companies.
4. Licensing business
We are looking for licensing opportunities for our Seeplex products with molecular diagnostic
companies or instrument companies.
Product /
Technology
Availability
Development
Phase
Area
Technology Type
ACP (Annealing
Control Primer)
Technology
DPO (Dual Priming
Oligo) Technology
Technology
Seeplex 18-plex
HPV Genotyping
Test
Seeplex 7-plex STD
Detection Test
Seeplex-11plex
Respiratory Viruses
Seeplex-23 plex
STD test
Seeplex-27-plex
Respiratory
Pathogens
Seeplex-4plex
Lamivudineresistant HBV
Sssplex 3-plex
Mycobacteria Test
Preclinical
Available
licensing
Available
licensing
Available
licensing
Available
licensing
for out-
n/a
for out-
n/a
for out-
n/a
for out-
n/a
Respiratory
Biotech Product
n/a
Infectious and
parasitic diseases
Biotech Product
n/a
Infectious and
parasitic diseases
Biotech Product
Clinical
Development
Tools
Infectious and
parasitic diseases
Technology
Biotech Product
Biotech Product
Respiratory
Biotech Product
Biotech Product
47
Small Bone Innovations, Inc.
Mr. Anthony G. Viscogliosi
Chairman and CEO
New York, New York
United States
www.totalsmallbone.com
Founded: 2004
Employees: 130
To create dominant franchise value through recognition as the first company to focus exclusively on
treatment of small bone and joint arthroplasty and reconstruction.
Ownership: Private
Main Sector:
Subsectors:
Medical Technology
Non-active implantable devices
SBi is committed to becoming a leader in the design, development and marketing of more than 60
product systems for upper and lower limb arthroplasty, internal fixation, external fixation and tissue
technology.
Collaborations:
Acquire or license technologies/products.
Provide resources including funding to surgeons and others to develop or expand use of technologies.
Provide grants etc. to non-profit institutions for clinical research.
48
Stereotaxis
Michael Kaminsik
President and COO
St. Louis, Missouri
United States
www.stereotaxis.com
Founded: 1991
Employees: 180
Stereotaxis’ proprietary magnetic systems and disposable devices allow physicians’ to conduct
precise, image-guided, computerized remote control interventional procedures designed to provide
greater efficacy, efficiency, predictability, ease of use and safety for both routine and complex
procedures in electrophysiology and interventional cardiology, including procedures in arrhythmia
diagnosis and ablation, cardiac resynchronization therapy and complex occlusion recanalization.
Physicians direct procedures from outside the x-ray field via a digital user interface with “point and
click”, “joystick” and “push button” controls. Stereotaxis has integrated its products with leading cath
lab imaging technologies through alliances with industry leaders. The Company’s core products have
regulatory clearances and approvals in the U.S., Europe, Canada and Asia.
IPO: 2004
Main Sector:
Subsectors:
Medical Technology
Single-use devices
Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for
use in a hospital's interventional surgical suite to enhance the treatment of coronary artery disease
and arrhythmias. The Stereotaxis System is designed to enable physicians to complete more complex
interventional procedures by providing image guided delivery of catheters and guidewires through
the blood vessels and chambers of the heart to treatment sites. This is achieved using computercontrolled, externally applied magnetic fields that govern the motion of the working tip of the
catheter or guidewire, resulting in improved navigation, shorter procedure time and reduced x-ray
exposure.
Collaborations:
Stereotaxis has formed, and continues to build on, critical strategic alliances with leading companies
in the medical technology industry and also to build relationships with certain important OEM and
specialty software providers. The Company’s collaborations include co-development of new devices
and other products, advanced software and hardware integration of imaging modalities, comarketing and co-selling of devices and coordinated provision of service on a worldwide basis. We
are privileged to have formed partnerships with the leading companies in the cardiac cath lab
industry and to enjoy the substantial and continuing support that they have provided for
commercialization of our technology. These companies include Biosense Webster, a Johnson &
Johnson Company; Siemens; and Philips.
49
Sunshine Heart, Inc.
Mr. Donald Gene Rohrbaugh
CEO
Tustin, California
United States
www.sunshineheart.com
Founded: 2000
Employees: 25
Innovative medical device therapy to treat patients in moderate heart failure
Ownership: Public
IPO: 2004
Ticker: SHC
Stock Exchange: ASX
Main Sector:
Subsectors:
Medical Technology
C-Pulse is a simple, novel implant that involves minimal invasive surgery to increase the heart's cardiac
output, reduce the heart's workload ad increase the heart's coronary perfusion.
It is the first and only non-blood contacting heart assist device in clinical trials.
Collaborations:
Company has utilized outsourced manufacturing and clinical partners .
With CE Mark, the Company will seek an OUS marketing partner
Product /
Technology
Availability
Development
Phase
C-Pulse
In development
Development
50
Area
Technology Type
Active
implantable
devices
Medtech Product
SyntheMed, Inc.
Mr. Robert Patrick Hickey
President & CEO
Iselin, New Jersey
United States
www.synthemed.com
Founded: 1990
Employees: 8
SyntheMed, Inc. is a biomaterials company engaged primarily in the development and
commercialization of anti-adhesion and drug delivery products. Products under development, all of
which are based on the company's proprietary bioresorbable polymer technology, are primarily
medical devices designed to prevent or reduce the formation of adhesions (scar tissue) following a
broad range of surgical procedures.
Ownership: Public
IPO: 1991
Ticker: SYMD
Stock Exchange: other
Main Sector:
Subsectors:
Medical Technology
Non-active implantable devices
Biomaterials
Coatings
Delivery
REPEL-CV® Adhesion Barrier is a thin, bioresorbable film that is placed on the epicardial surface of the
heart during a cardiac surgical procedure to reduce the formation of post-operative adhesions.
REPEL-CV has CE Mark approval and is marketed outside the US and is pending FDA approval.
Other products under development:
•
•
•
REPEL-AFIB™ , a site-specific drug delivery vehicle, in this case in the form of a bioresorbable
film similar to REPEL-CV, which is impregnated with an anti-arrythmic drug designed to be
paced on the surface of the heart during an open heart surgical procedure. The objective is to
deliver the drug to the myocardium as the film resorbs thereby preventing the onset of
surgically-induced atrial fibrillation.
RESOLVE™, a viscous solution used as an instillate that is either poured (open procedures) or
injected (laparoscopic procedures) into the peritoneal cavity to reduce the formation of postoperative adhesions in gynecologic and bowel procedures by coating the traumatized tissue
surfaces.
RELIEVE™, a viscous reverse thermal gel used in spine and tendon surgery to coat the
traumatized tissue surfaces and thus reduce the formation of post-operative adhesions.
51
Collaborations:
Partner with companies with strong product franchises in gynecologic surgery, spine surgery among
others with a shared objective of improving patient outcomes through the development of safe and
effective anti-adhesion products.
Partner with medical device companies seeking to improve product performance through the
incorporation of bioresorbable polymer materials.
Partner with pharmaceutical and biotechnology companies seeking to deliver therapeutic agents on
a site-specific basis through the use of bioresorbable polymer-based delivery vehicles.
Product /
Technology
Availability
Bioresorbable
Polymer
RELIEVE
In development
Development
REPEL-AFIB
In development
Development
REPEL-CV
On the Market
RESOLVE
In development
Development
52
Development
Phase
Area
Technology Type
Drug
delivery/formulation
technology
Non-active
implantable
devices
Active implantable
devices
Non-active
implantable
devices
Non-active
implantable
devices
Technology
Medtech Product
Medtech Product
Medtech Product
Medtech Product
TissueLink Medical, Inc.
Mr. Lawrence E. Yost
Director of Marketing
Dover, New Hampshire
United States
www.tissuelink.com
Founded: 1999
Mission / Baclground:
TissueLink Medical is a private, venture capital backed Company founded in 1999 which develops
and markets devices based on a proprietary saline-coupled radio-frequency technology. This
technology is used to control bleeding and improve patient outcomes during a wide variety of
surgical procedures.
Ownership: Private
Main Sector:
Subsectors:
Medical Technology
Single use devices
TissueLink's current focus is the promotion of the Aquamantys System™ for reducing blood transfusions,
improving visualization, and decreasing bleeding related complications in association with total joint
replacement and instrumented spine procedures. The Company also markets a line of monopolar
devices based on TissueLink's platform technology which are used to reduce bleeding and assist with
solid organ resection.
53
Victhom Human Bionics
Mr. Benoit Huet
President & Chief Executive Officer
St-Augustin-de-Desmaures, Quebec
Canada
www.victhom.com
Founded: 2000
Employees: 70
Victhom discovers, develops and manufactures bionic devices involved in the treatment of a variety
of physical and physiological dysfunctions. Victhom's Neurobionix business unit focuses on the
development and commercialization of technologies and products involving implantable devices
that feature neurosensing and neurostimulation components, integrated with artificial intelligence.
Victhom's Biotronix business unit develops biomechatronic products to support or replace peripheral
limbs in what is known as the orthotics and prosthetics (or “O&P”) market.
Ownership: Public
IPO: 2002
Ticker: VHB
Stock Exchange: TSX
Main Sector:
Subsectors:
Medical Technology
Other
The Power Knee is the world's first and only motor-powered, artificially intelligent prosthesis for aboveknee amputees. The Neurostep is an implantable device that features neurosensing and
neurostimulation capabilities for peripheral nerves. It is designed to treat, through neuromodulation,
gait disorders (e.g. foot drop) which can result from a lesion of the central nervous system caused by
conditions such as stroke and multiple sclerosis.
Collaborations:
For its Neurobionix business unit, Victhom's strategy is to complete the ongoing clinical trials of its
Neurostep to register the product with the European and American health authorities and then
commercialize the product with partners in those regions.For its Biotronix business unit, Victhom is
focused on its partnership with Össur. Under the terms of its agreements with Össur, the parties are
developing and pioneering products to enhance the quality of life of people with physical disabilities.
54
Xthetix, Inc.
Mr. Brian D. O'Connor
CEO
Mesa, Arizona
United States
www.xthetix.com
Founded: 2006
Xthetix, Inc., is a skincare medical device company formed to develop, manufacture and market
novel therapeutic ultrasound products for the expanding over-the-counter (OTC) aesthetics market.
The company's products include devices for acne treatment and prevention along with devices
addressing facial skin rejuvenation. The Xthetix products are presently being incubated by Arizonabased Guided Therapy Systems, LLC, a developer of novel therapeutic ultrasound technologies. In
2004, Ulthera Inc., another Guided Therapy company was spun off to commercialize devices for nonsurgical face lift procedures. The distinction between the two is that Ulthera (pending FDA approval)
addresses the professional market, while Xthetix is developing consumer applications which will be sold
over-the-counter without a prescription.
Ownership: Private
Main Sector:
Subsectors:
Medical Technology
Other
Xthetix's ultrasound devices can deposit heat directly into the sebaceous glands and hair follicle,
inhibiting the secretion of sebum, thus preventing mild to moderate acne from erupting. In essence, it
is designed to act like acne drugs that inhibit sebaceous gland function; however, it uses thermal
energy instead of a systemic approach.
The device consists of a handle that houses a rechargeable battery and a series of disposable
treatment tips for different applications, including skin rejuvenation. Xthetix will earn recurring revenues
from sales of the disposable tips and a companion line of cosmeceuticals.
Xthetix has completed initial safety studies and is now conducting dose/response clinical studies.
Collaborations:
Xthetix invites interested parties to participate in the current Series B round of $8.0 million.
Xthetix encourages a strategic relationship with a company currently commercializing products in the
consumer skin care segment.
Xthetix wishes to help facilitate the the outlicensing of IP under the GTS Technology to develop,
manufacture and sell products using high intensity ultrasound imaging/therapy transducer technology
and ultrasound electronics for multiple treatment application FIELDS.
Product /
Technology
Therapeutic
ultrasound
Availability
Development
Phase
Area
Technology Type
Technology
55

Presenting Companies

Transcription

Similar documents

Project Profile – MedTech College - C-CAT

AdvaMed 2014: hot topics •

Teams, Not Individuals, Will Rule the New Medtech SalesLandscape

The European Medical Technology Industry in Figures

2016- 2018 Strategic Plan LAKE COUNTY YMCA

The European Medical Technology Industry in Figures

Carman scan lite for Fyfes

Texas Treasure Business Award

Material on this site may be quoted or reproduced for personal and

digital slides

Recent Developments in Active Implants